Guidant to use CardioVascular's Focus technology:
This article was originally published in Clinica
Executive Summary
Guidant's Vascular Intervention Group is to develop and market CardioVascular Dynamics' Focus technology in products designed to deliver Guidant's coronary and vascular stents. Guidant has exclusive rights to the technology for stent delivery in the US and Canada, and co-exclusive rights with CVD for the rest of the world. Irvine, California-based CVD will continue to sell the technology for balloon dilation procedures in the US and all applications elsewhere. Guidant will make payments to CVD, linked to the transfer of manufacturing technology and know-how, as well as royalties. CVD says its technology provides a unique method of performing coronary stent delivery using both low and high balloon inflation pressures on a single catheter.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.